Float Short %

2.43

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.01

EPS Last/This Y

41.67

EPS This/Next Y

0.1

Price

9.43

Target Price

20.7

Analyst Recom

Performance Q

-49.6

Relative Volume

4.46

Beta

0.64

Ticker: ALVR

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	ALVR	0.4622	N/A	N/A	0
2024-12-20	ALVR	0.4218	N/A	N/A	0
2024-12-23	ALVR	0.4584	N/A	N/A	0
2024-12-24	ALVR	0.4742	N/A	N/A	0
2024-12-26	ALVR	0.4735	0.10	0.00	299
2024-12-27	ALVR	0.445	0.10	0.00	299
2024-12-30	ALVR	0.4477	0.10	0.00	299
2024-12-31	ALVR	0.421	0.10	0.00	299
2025-01-02	ALVR	0.45	0.10	0.00	299
2025-01-03	ALVR	0.443	N/A	N/A	0
2025-01-06	ALVR	0.4729	0.00	0.00	682
2025-01-07	ALVR	0.4701	0.00	0.00	687
2025-01-08	ALVR	0.445	0.00	0.00	687
2025-01-09	ALVR	0.4498	0.00	0.00	687
2025-01-10	ALVR	0.433	0.00	0.00	687
2025-01-13	ALVR	0.402	0.00	0.00	687
2025-01-14	ALVR	0.3975	0.00	0.00	687
2025-01-15	ALVR	0.3872	N/A	N/A	0
2025-01-16	ALVR	9	N/A	N/A	0
2025-01-17	ALVR	9.425	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	ALVR	0.45	-	-	-0.42
2024-12-20	ALVR	0.42	-	-	-0.42
2024-12-23	ALVR	0.45	-	-	-0.42
2024-12-24	ALVR	0.47	-	-	-0.42
2024-12-26	ALVR	0.47	-	-	-0.42
2024-12-27	ALVR	0.46	-	-	-0.42
2024-12-30	ALVR	0.45	-	-	-0.42
2024-12-31	ALVR	0.43	-	-	-0.42
2025-01-02	ALVR	0.45	-	-	-0.42
2025-01-03	ALVR	0.45	-	-	-0.42
2025-01-06	ALVR	0.47	-	-	-0.42
2025-01-07	ALVR	0.47	-	-	-0.42
2025-01-08	ALVR	0.45	-	-	-0.42
2025-01-09	ALVR	0.45	-	-	-0.42
2025-01-10	ALVR	0.44	-	-	-0.42
2025-01-13	ALVR	0.41	-	-	-0.42
2025-01-14	ALVR	0.40	-	-	-0.42
2025-01-15	ALVR	0.39	-	-	-0.42
2025-01-16	ALVR	9.00	-	-	-0.42
2025-01-17	ALVR	9.43	-	-	-0.42
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	ALVR	-0.16	-9.31	3.72
2024-12-20	ALVR	-0.16	-9.31	3.72
2024-12-23	ALVR	-0.18	-9.31	3.72
2024-12-24	ALVR	-0.18	-9.31	3.72
2024-12-26	ALVR	-0.15	-9.31	3.27
2024-12-27	ALVR	-0.16	-9.31	3.27
2024-12-30	ALVR	-0.17	-9.37	3.27
2024-12-31	ALVR	-0.17	-9.37	3.27
2025-01-02	ALVR	-0.17	-9.37	3.27
2025-01-03	ALVR	-0.16	-9.37	3.27
2025-01-06	ALVR	-0.16	-10.27	3.27
2025-01-07	ALVR	-0.16	-10.27	3.27
2025-01-08	ALVR	-0.16	-10.27	3.27
2025-01-09	ALVR	-0.16	-10.27	3.27
2025-01-10	ALVR	-0.16	-10.27	3.27
2025-01-13	ALVR	-0.16	-10.27	2.43
2025-01-14	ALVR	-0.16	-10.27	2.43
2025-01-15	ALVR	-0.16	-10.27	2.43
2025-01-16	ALVR	-0.16	-10.27	2.43
2025-01-17	ALVR	-3.58	-10.27	2.43
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.09

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

-3.58

Institutional Transactions

-10.27

Beta

0.64

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

94.3

Max Drawdown 5-Year %

Target Price

20.7

P/E

Forward P/E

PEG

P/S

P/B

0.38

P/Free Cash Flow

EPS

-20.16

Average EPS Est. Cur. Y

-0.42

EPS Next Y. (Est.)

-0.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

4.46

Return on Equity vs Sector %

-101.8

Return on Equity vs Industry %

-89.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.12

EBIT Estimation

AlloVir, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 8

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

stock quote shares ALVR – AlloVir, Inc. Stock Price stock today

news today ALVR – AlloVir, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALVR – AlloVir, Inc. yahoo finance google finance

stock history ALVR – AlloVir, Inc. invest stock market

stock prices ALVR premarket after hours

ticker ALVR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALVR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y